Analysts Issue Forecasts for DRTS Q1 Earnings

Posted by on May 21st, 2026

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Alpha Tau Medical in a report issued on Wednesday, May 20th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q4 2027 earnings at ($0.14) EPS.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last issued its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

A number of other research analysts have also recently weighed in on DRTS. Citigroup raised their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Piper Sandler raised their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday. LADENBURG THALM/SH SH raised their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Finally, Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $11.50.

Read Our Latest Stock Analysis on Alpha Tau Medical

Alpha Tau Medical Trading Up 4.7%

Shares of DRTS opened at $11.18 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.45. The firm has a 50 day simple moving average of $7.88 and a 200-day simple moving average of $6.47. Alpha Tau Medical has a 1-year low of $2.81 and a 1-year high of $11.62. The stock has a market cap of $983.95 million, a price-to-earnings ratio of -16.69 and a beta of 1.11.

Institutional Trading of Alpha Tau Medical

A number of hedge funds have recently bought and sold shares of the company. Mariner LLC boosted its position in Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after acquiring an additional 1,915 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new stake in Alpha Tau Medical during the fourth quarter worth approximately $48,000. Levin Capital Strategies L.P. boosted its position in Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after acquiring an additional 12,200 shares during the last quarter. Envestnet Asset Management Inc. acquired a new stake in Alpha Tau Medical during the third quarter worth approximately $62,000. Finally, Wells Fargo & Company MN boosted its position in Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after acquiring an additional 17,500 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

Featured Stories

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.